



National Association of State
Controlled Substances Authorities

NASCSA Resolution 2022-01
October 2022
Salt Lake City, Utah

**A Resolution Relative to Scheduling Gabapentin and Gabapentin Enacarbil as
a Schedule V Controlled Substance**

WHEREAS, the purpose of the National Association of State Controlled Substances Authorities (NASCSA) is to provide a continuing mechanism through which states, federal agencies, and others can work to increase the effectiveness and efficiency of state and national efforts to prevent prescription drug diversion and abuse; and

WHEREAS, recognizing the potential abuse, several states have already classified gabapentin as a Schedule V controlled; and

WHEREAS, at least 12 states require gabapentin be tracked via the Prescription Drug Monitoring Program; and

WHEREAS, a Citizens Petition has been filed under Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. § 811) and under Drug Enforcement Administration (DEA) regulations at 21 C.F.R. § 1308 and Food and Drug Administration (FDA) regulations at 21 C.F.R § 10.30 to request that the DEA Administrator and the Commissioner of Food and Drugs initiate the proceedings to place (a) gabapentin (2-[1- (aminomethyl) cyclohexyl] acetic acid), including its salts, (including the brand name products Gralise and Neurontin) and (b) gabapentin enacarbil (1-[[[[(1RS)-1-[(2-methylpropanoyl)oxy] ethoxy]carbonyl]amino]methyl] cyclohexyl) acetic acid), including its salts, (including the brand name product Horizant) into Schedule V of the CSA; and

WHEREAS, In March 2022 NASCSA conducted a survey of regular members soliciting input on gabapentin and gabapentin enacarbil in which 82% of the respondents indicated their support for placing the drug as a Schedule V Controlled Substance and 35% indicated the drug was not a concern in their particular state;

NOW, THEREFORE BE IT RESOLVED, that NASCSA encourages DEA and FDA to place gabapentin and gabapentin enacarbil as a Schedule V drug under the Controlled Substances Act and encourages states, districts and territories to consider similar scheduling action; and

BE IT FURTHER RESOLVED, that NASCSA communicate to its membership, DEA and FDA its support for scheduling these drugs.

ATTEST: _____ *Alan J McGill* _____
President

DATE: October 26, 2022